ArticleStroke and vascular neurology2026
Multimodal MRI habitat atlas for personalised re-haemorrhage risk prediction in brainstem cavernous malformations.
Article in Stroke and vascular neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop an MRI habitat atlas that is robust across different haemorrhage stages for haemorrhagic brainstem cavernous malformations (BSCMs) and to integrate habitat-derived imaging biomarkers with clinical variables for precise prediction of symptomatic re-haemorrhage.
methodsA retrospective cohort of 205 eligible patients from Huashan Main Campus (2015-2020) was randomly divided into a discovery set (n=147) for model development and an internal validation set (n=58). External validation was performed using a prospective temporal cohort from Huashan West Campus (2021-2023, n=94). Each lesion was segmented into six biologically distinct habitats via unsupervised clustering of multiparametric MRI. Habitat-derived radiomic features were combined with clinical variables into a multimodal logistic regression model, which was rigorously validated both internally and temporally.
resultsThe 2-year cumulative re-haemorrhage rate was 81% in high-risk lesions versus 26% in low-risk lesions. The combined habitat-clinical model achieved an area under the curve (AUC) of 0.833 (95% CI 0.777 to 0.889) in the training set and 0.851 in the external validation set, significantly outperforming both imaging-only (∆AUC+0.07, p=0.008) and clinical-only models (∆AUC+0.17, p<0.001). The model demonstrated excellent calibration and provided net clinical benefit across decision thresholds of 5%-75%.
conclusionThe multimodal MRI habitat atlas provides a robust and reproducible tool for individualised re-haemorrhage risk stratification in BSCMs, facilitating clinical decision-making for surveillance or intervention while reducing the likelihood of overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.